Receptors containing these mutant subunits display much larger currents and a higher sensitivity to acetylcholine than wild-type receptors. Recently, the I279N mutation has been discovered in the first transmembrane spanning segment of "CHRNA2", which encodes a nicotinic acetylcholine receptor α2 subunit similar to the nAChR α4 encoded by "CHRNA4". This mutant shows a higher sensitivity to acetylcholine and unchanged desensitization compared to wild-type. Diagnosis is typically made upon patient history, although EEG recordings can be confirmatory if they occur during attacks. Anti-epileptic drugs are normally used to combat ADNFLE. These drugs are discussed in the main epilepsy article.